Annalisa Trama, MD, PhD



Annalisa Trama, is the Director of the Evaluative Epidemiology Unit at the Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy, where she also serves as Coordinator of the INT Institutional Strategic Research Priority on rare cancers and complexity in oncology.

Her research activities focus on rare cancers and adolescent and young adult cancers. She is an expert in population-based research including population-based cancer registries and administrative dataset. She was a founder of RARECARE (surveillance of rare cancers in Europe) which proposed a definition for rare cancer. She was the founder of RARECAREnet Asia, a collaboration between European and Asian population-based cancer registries (CRs) on rare cancers. In the area of rare cancers, she co-coordinated the Joint Action on Rare Cancers (JARC), carried out between 2016 and 2019 within the framework of the Third Health Programme of the European Union (EU) with 34 partners and 18 EU Member States. She coordinates the clinical registry of EURACAN, the European Reference Network on rare adult solid cancers. She was a founder of the first Italian adolescent and young (AYA) cancer survivor cohort and she coordinates the Steering committee of this cohort. She is a member of the Scientific Coordination of EUROCARE (surveillance of cancer patients in Europe).

She is (co)author of more than 100 papers in peer-reviewed medical journals.

Anne-Marie C. Dingemans MD, PhD is a pulmonologist and a professor of thoracic oncology. Since September 2019 she is a staff member of the department of pulmonary medicine at Erasmus Medical Center, Rotterdam, The Netherlands. Between 2004 and 2019 she was appointed as a staff member at the department of pulmonary medicine at Maastricht University Medical Center+. She received her medical degree at Maastricht University in 1994 and subsequently her PhD at VU Medical Center Amsterdam in 2000 for laboratory research on resistance to chemotherapy in lung cancer. She performed her training for respiratory physician at VU Medical Center in Amsterdam and Leiden University Medical Center. Currently she is involved in translational research on lung cancer, with special interest in neuroendocrine lung tumors, driver mutations and oligometastatic disease.
Since January 2021 she is chair of the EORTC lung cancer group. She was involved in the EORTC initiative to develop a consensus definition on synchronous oligometastatic NSCLC. She is member of IASLC, AACR, ASCO, ERS, ESMO and ETOP. She is associate editor of the Journal of Thoracic Oncology and editorial board member of the International IASLC Lung Cancer News. She has (co)-authored more than 230 publications and book chapters.

Hello! My name is Sonia Oyola. I have had the privilege of being a Family Medicine Physician since 2000 after completing medical school at the University of Illinois College of Medicine in 1997 and my residency at Cook County's Family Medicine Residency in 2000. I then completed a fellowship at the University of Arizona's Center for Integrative Medicine in 2013 and am currently the Director of Medical Student Education, the director of the Family Medicine Elective and co-director of the Culinary Medicine Programs for the Department of Family Medicine at the University of Chicago's Pritzker School of Medicine. I'm fortunate to see my patients at Heartland Health Centers in a neighborhood called Rogers Park in Chicago. My specific interests are in Integrative Primary Care, Domestic Violence, Stress Disorders, Mind-Body Medicine (particularly Meditation, Yoga and Breathwork), Trauma-Informed Care, Poetry/Narrative Medicine and Culinary Medicine. Lastly, in 2009 I founded a nonprofit organization called Be Alright which supports survivors of domestic violence and Chicago-area DV shelters. My life's mission is to relieve suffering through mindfulness, kindness, joy and the promotion of compassion.

Gary Rodin is a Professor of Psychiatry and Director of the Global Institute of Psychosocial, Palliative and End-of-Life Care (GIPPEC) at the University of Toronto. He is also the inaugural Director of the Cancer Experience Program , a comprehensive program at the University Health Network to support the interconnected well-being of patients, families, staff and trainees. Dr. Rodin leads an internationally recognized clinical and research program at the Princess Margaret Cancer Centre focused on the development, evaluation and global implementation of novel interventions to improve the psychological wellbeing and quality of life of patients with cancer and their families. He has published widely in these areas and has been recognized for his global efforts to ensure universal access to psychosocial and palliative interventions and optimal end-of-life care for patients and families facing advanced disease.

Celia is the Clinical Lead for Occupational Therapy at Peter MacCallum Cancer Centre, Research Lead at Royal Melbourne Hospital and is a PhD candidate at University Of Technology in Sydney. She has specialised in oncology and palliative care for more than 15 years. Celia's PhD topic is titled "optimising transitions from hospital to home for people with palliative care needs"; with a particular focus on interventions that support carers of people with advanced cancer. She has 12 peer-reviewed publications and has been successful in recent grants supporting health service research in cancer care. Her research interests lie in exploring allied health interventions in cancer care and aged care rehabilitation; and building an evidence base through the conduct of clinical trials for complex interventions.

Dr. Noemi Reguart earned her Medical Degree from the University of Medicine Lleida, in Spain. She completed her postgraduate training and fellowship in the Oncology Department at Hospital Clinic Barcelona. Dr. Reguart gained a PhD focusing on molecular lung cancer biology at the University of California San Francisco (UCSF).
She has practiced as a Consultant Oncologist at the Department of Medical Oncology in Hospital Clinic Barcelona since 2008. She is a Clinical Professor at the University of Barcelona, deeply committed to under- and postgraduate teaching. Most recently Dr. Reguart has been designated the Director of the Thoracic Oncology Unit at the Hospital Clínic.
Throughout her career, Dr. Reguart has shown her interest in addressing lung cancer. She has been involved in the design and patient recruitment to many personalized lung cancer trials. In addition to clinical practice and patient care, she also conducts basic research with a special interest in lung cancer biomarkers and the identification of predictors of therapy response at the Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory in August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona. She has always maintained an active research interest in her own laboratory as well as through several national and international collaborations.
Dr. Reguart is an active member of several international lung cancer organizations including the European Society for Medical Oncology (ESMO), the International Association for the Study of Lung Cancer (IASLC) and the Spanish Lung Cancer Group (SLCG). She is a member of the Board of Directors the Lung Cancer Group of the European Organization for Research and Treatment of Cancer (EORTC) and the author of several scientific publications in the field.

Stéphane Champiat MD, PhD is a full-time attending physician at Gustave Roussy Cancer Center in Villejuif, France. He completed his medical oncology residency at the University of Nantes in 2014 and taught as an assistant Professor at Paris-Saclay University between 2017 and 2019.
He worked at the University of California San Francisco (UCSF) between 2009 and 2010 as a postdoctoral researcher in Immunology and defended a PhD in Immunology at the Université Paris-Saclay in 2019.
Stéphane Champiat is working since 2012 in the Drug Development Department of Gustave Roussy (DITEP) where he is involved in the development of cancer therapeutics, in particular new immunotherapies. He has been principal investigator or co-investigator of more than 50 phase 1 clinical trials. He is particularly involved in the coordination of the immunotherapy toxicity management program and the development of the intra-tumoral immunotherapy strategy at Gustave Roussy.
As part of the Immunotherapy Translationnal Research Lab (LRTI), his research topics include mechanisms of resistance, efficacy and toxicity of immunotherapies.